Pharma Mar
Pharma Mar, officially known as Pharma Mar S.A., is a leading biopharmaceutical company headquartered in Madrid, Spain. Founded in 1986, the company has established itself as a pioneer in the research and development of marine-derived medicines, particularly in the oncology sector. With a strong focus on innovative therapies, Pharma Mar has made significant strides in the treatment of cancer, leveraging unique compounds sourced from the ocean. The company’s flagship products, including Yondelis and Aplidin, are distinguished by their novel mechanisms of action and have garnered attention in both clinical and commercial arenas. Pharma Mar's commitment to advancing cancer treatment has positioned it as a key player in the global biopharmaceutical landscape, with a robust pipeline and strategic partnerships enhancing its market presence.
DitchCarbon Score
How does Pharma Mar's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharma Mar's score of 83 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharma Mar's reported carbon emissions
In 2024, Pharma Mar reported total carbon emissions of approximately 17,719,000 kg CO2e, with Scope 1 emissions at about 1,340,000 kg CO2e, Scope 2 emissions at approximately 247,000 kg CO2e, and a significant contribution from Scope 3 emissions, which totalled around 16,132,000 kg CO2e. This represents a slight decrease from 2023, where total emissions were about 17,850,000 kg CO2e. Pharma Mar has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 emissions by 42% by 2030 from a 2021 baseline. Additionally, the company has committed to a long-term target of reducing total emissions across all scopes (1, 2, and 3) by 90% by 2050, also from a 2021 baseline. These targets have been validated by the Science Based Targets initiative (SBTi) and are aligned with the goal of limiting global warming to 1.5°C. The company’s emissions data is sourced directly from Pharma Mar, S.A., with no cascading from a parent or related organization. This commitment to sustainability reflects Pharma Mar's proactive approach to addressing climate change within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 1,373,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,237,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 3 | 12,449,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharma Mar is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
